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Thirty two compounds were synthesized in moderate to high yields and showed activity against cancer
cells HL-60 (leukemia), MDA-MB435 (melanoma), HCT-8 (colon) and SF295 (central nervous system),
with IC50 below 2 mM for some compounds. The b-lapachone-based 1,2,3-triazoles showed the best
cytoxicity proﬁle and emerge as promising anticancer prototypes. Insights about the reactive oxygen
species (ROS) mechanism of anticancer action for some compounds were obtained by addition of
1-bromoheptane that deplete reduced glutathione (GSH) content and by using N-acetylcysteine that
protects cells against apoptotic cellular death, as well by analysis of thiobarbituric acid reactive
substances (TBARS) formation, and oxidative DNA damage after treatment detected by the comet assay
with the bacterial enzymes formamidopyrimidine DNA-glycosylase (FPG) and endonuclease III (ENDOIII).
 2010 Elsevier Masson SAS. Open access under the Elsevier OA license.1. Introduction
Naphthoquinones (NQs) have been the subject of much research
due to their pharmacological activities [1e4].
Recently, shikonin, rhinacanthin and juglone derivatives [4e6],
lapachol analogues [7,8], copper(II) complexes [9] obtained from
lawsone have been described as antitumoral and are examples of
the importance of natural products analogues as source of antitu-
moral compounds.
Several strategies are used to obtain newactive compounds from
natural products, as for instance, bioisosterism [10] and molecular
hybridization [11] and in the last years the employment of click
reactions [12] along with those strategies made possible the pre-
paration of several heterocycles with antitumor activities [13].
Aiming to discover cytotoxic NQs, in the last few years, we have
synthesized and evaluated the antitumor activity of naphthodi-
hydrofuranquinones obtained from nor-lapachol, as for instance,dutos Naturais, UFRJ, 21944-
fax: þ55 21 25626512.
. da Silva).
Pinto due to his wonderful
nder the Elsevier OA license.nor-b-lapachone-based 1,2,3-triazoles [14], arylamino and alkoxy
derivatives [15,16].
In continuity of our program for obtaining new substances from
NQs with pharmacological activity, we prepared three classes of
compounds. Recently, our research group, based on the studies of
Ettlinger [17] and Anufriev [18], described the correct structure for
Hooker’s lapachol peroxide by X-ray crystallography [19]. Upon the
use of this reaction, we synthesized the ﬁrst class of compounds.
Anthraquinone imidazoles constitute the second group and ﬁnally,
using the approach of molecular hybridization [11], b-lapachone-
based 1,2,3-triazoles, the third group, were prepared [20]. The
trypanocidal activity against Trypanosoma cruzi of few of them has
already been reported [20].
2. Chemistry
Lapachol (1) (2-hydroxy-3-(30-methyl-20-butenyl)-1,4-naphtho-
quinone) was extracted from the heartwood of Tabebuia sp. (Tecoma)
and puriﬁed by a series of recrystallizations [21]. From this quinone,
nor-lapachol (2) (2-hydroxy-3-(20-methyl-propenyl)-1,4-naphtho-
quinone) was obtained by Hooker oxidation method [22].
The reduced quinones 7 and 9 synthesized from lapachol (1), 3
and 5 from nor-lapachol (2) and 13 and 15 from C-allyl lawsone (11)
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Scheme 1. Reagents and conditions: (i) EtOH, 10 mol % Pd/C, 30 psi of H2, 15 min; (ii) AcOH, 10 mol % Pd/C, 55 psi of H2, 6 h; (iii) AcOH, PbO2.
O
O
OH
O
O
OH O
O
O
O
O
O
O
O
OH O
O
O
O
O
O
O
O
O
O
O
O
i
ii
iii
iii
iii
11 12, 75%
13 , 90% 14, 70%
15, 98% 16, 75%
Scheme 2. Reagents and conditions: (i) EtOH, 10 mol % Pd/C, 30 psi of H2, 15 min; (ii)
AcOH, 10 mol % Pd/C, 55 psi of H2, 6 h; (iii) AcOH, PbO2.
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Using the Hooker’s reaction with PbO2 [19], these reduced
compounds were used to prepare ether derivatives 4, 6, 8,10,12,14
and 16, in good yields (Schemes 1 and 2). Syntheses of these ethers
are easily accomplished by heating glacial acetic acid and lead
dioxide. The reaction is ﬁnished in 2 min and after ﬁltration to
remove lead oxide, the products were puriﬁed by recrystallization
and obtained as yellow crystals. Silica gel column chromatography
should be avoided, once it favours the cleavage of the CeOeC
bonds.
Finally, we applied the reaction of oxidative coupling with PbO2
in phthiocol (Scheme 3) and an unexpected product 17 was
obtained. Besides elucidating the structure by the use ofO
O
Me
OH
PbO2
AcOH
Phthiocol
O
O
Me
O
O
O
Me
17
Scheme 3. Synthesis of compound 17.spectroscopic techniques, yellow crystals were obtained and the
structure was reconﬁrmed by crystallographic methods. Ortep-3
diagram of the molecule is shown in Fig. 1, and Table 1 lists main
crystallographic parameters.
The second series is constituted by anthraquinone imidazoles
18e28. All the substances are herein described for the ﬁrst time,
except compounds 18 and 24 [20,23]. All of them are easily
obtained from the reaction of 1,2-diaminoanthracene-9,10-dione
(17a) and substituted aldehydes (Scheme 4).
The b-lapachone-based 1,2,3-triazoles 33e36 were synthesized
as previously described [20]. These compoundswere obtained from
b-lapachone (29), synthesized by acid cyclisation of lapachol (1).
N-bromosuccinimide (NBS) in CCl4 with benzoyl peroxide as initi-
ator were used to obtain 3,4-dibromo-b-lapachone (30) [24]. Sub-
stances 31 and 32 were separated by column chromatography and
compound 32 was submitted to azide-alkyne Huisgen’s cyclo-
addition catalysed by Cu(I) [25], producing the 1,2,3-triazoles
33e36 (Fig. 2).
The structures of compoundswere conﬁrmedby techniques such
as 1H and 13C NMR, IR, high-resolution (electrospray ionization)
mass spectra and spectroscopic data in comparison with related
compounds [19,26]. Spectral data for the new ones are included.Fig. 1. An ORTEP-3 projection, showing the atomic labelling and the 50% probability
ellipsoids of the compound 17.
Table 1
Crystal data and structure reﬁnement for compound 17.
Empirical formula C21H14O5$2H2O
Formula weight 355.95
Temperature 298(2) K
Wavelength 0.71073 Å
Crystal system Monoclinic
Space group P 21/a
Unit cell dimensions a ¼ 7.7078(3) Å
b ¼ 19.9585(11) Å
c ¼ 13.0416(6) Å
Volume 1978.02(10) Å3
Z 4
Density (calculated) 1.19 mg/m3
Absorption coefﬁcient 0.086 mm1
F(000) 747
Crystal size (0.242  0.225  0.132) mm3
Theta range for data collection 3.0e25.7
Index ranges 9  h  9
Reﬂections collected 15300
Independent reﬂections 3680 [R(int) ¼ 0.115]
Completeness to theta 97.0%
Absorption correction None
Max. and min. transmission 0.9913 and 0.9913
Reﬁnement method Full matrix least
Data/restraints/parameters 2171/0/255
Goodness-of-ﬁt on F2 1.024
Final R indices [I > 2sigma(I)] R1 ¼ 0.079, wR2 ¼ 0.130
R indices (all data) R1 ¼ 0.222, wR2 ¼ 0.272
Largest diff. peak and hole 0.378 and 0.255 e Å3
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All the substances herein described, except compounds 1, 2, 11,
17a and 30, were evaluated in vitro against four cancer cell lines HL-
60 (leukemia), MDA-MB435 (melanoma), HCT-8 (colon) and SF295
(central nervous system). Doxorubicin was used as the positive
control, based on the MTT assay (Table 2) [27]. The selectivity of
compounds toward a normal proliferating cell was investigated
using the Alamar Blue assay performed with peripheral blood
mononucluear cells (PBMC) after 72 h of drug exposure. Following
Pérez-Sacau et al. [7] the compounds were classiﬁed according to
their activity as highly active (IC50 < 2 mM), moderately active
(2mM < IC50 < 10 mM), or inactive (IC50 > 10 mM).
Despite positive results in terms of antitumor activity [7,28,29]
reduced compounds 3, 5, 7, 9, 13 and hybrid imidazoles were
inactive. However, antitumoral activity against the evaluated cancerO
O
NH2
NH2
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R1
R2
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AcO-Na+, AcOH
HNO
OReflux
17a
Scheme 4. Synthetic route for the preparatio
Fig. 2. Compounds 30e32 and b-Lapachone-based 1,2,3cell lineswas evidenced for all 1,2,3-triazole derivatives (33e36) and
intermediates 31 and 32. Themost signiﬁcant activity was observed
toward HL-60 and the compounds 32, 33 and 35were highly active
with IC50 values of 1.43, 1.01 and 1.20 mM, respectively. Considering
this cell line, these substances are as active as the prototype, b-
lapachone (29) (IC50 ¼ 1.65 mM).
For MDA-MB435, the activity of compounds 33e36 was signi-
ﬁcant with IC50 values below 2 mM. Only substance 33 was
considered highly active against HCT-8 cell lines with IC50 value of
1.37 mM. Against SF295 all the substances presented values within
the range 1.55e3.01 mM.
The most important cytotoxic mechanisms of quinonoid
compounds involve drug bioreduction, followed by reaction with
molecular oxygen and generation of ROS [1,29,30], and DNA
damage is considered to be the most serious ROS-induced cellular
modiﬁcations [31].
In fact, many of the effects of the chemical and physical agents
that are commonly used in the treatment of human malignancies
are mediated by induction of apoptosis. Nowadays, apoptosis has
currently been a target for developing antitumor drugs [32]. To
determine whether ROS are involved with quinonoid compounds-
induced cell death, cultures were pre-treated with 1-bromo-
heptane, a non-toxic reduced glutathione (GSH) depleting agent
[33] or pre-exposed to N-acetylcysteine (NAC), a widely used thiol-
containing antioxidant that is a precursor of GSH which protects
against oxidative stress-induced cell death by interacting with HO
and H2O2 [34]. Cell viability, morphological characterization of
apoptotic cancer cells, lipid peroxidation, and DNA-damaging
activities (i.e. DNA strand breaks and oxidized bases at the single-
cell level) were monitored after cell treatment with some repre-
sentatives of the above described three classes of compounds.
Cell membranes are often permeable to NQs, which, once,
present in cell, may form adducts with DNA, leading to abasic sites
and single or double strand breaks [35]. Initially, we correlated the
ability of the precursor molecules b- and nor-b-lapachone to
induce DNA strand breaks via intracellular ROS generation
(Table 3), highlighting the great importance of the production of
ROS on the antiproliferative effects of these NQs. Structure
modiﬁcations at the level of nucleotidic bases can also occur as
a consequence of oxidative stress. Oxidation of nucleotidic bases
is likely to be as important as DNA strand breaks to overall cellular
function and survival [36]. The most commonly used endonucle-
ases in the modiﬁed comet assay are formamidopyrimidineN
R1
R2
R3 18 - R1 = R2 = R3 = H
19 - R2 = R3 = H, R1 = F
20 - R1 = R3 = H, R2 = F
21 - R1 = R2 = H, R3 = F
22 - R2 = R3 = H, R1 = CH3
23 - R1 = R3 = H, R2 = CH3
24 - R1 = R2 = H, R3 = CH3
25 - R2 = R3 = H, R1 = OH
26 - R1 = R3 = H, R2 = OH
27 - R1 = R2 = H, R3 = OH
28 - R1 = H, R2 = OCH3, R3 = OH
n of imidazolic anthraquinones 18e28.
-triazoles 33e36 obtained from b-lapachone (29).
Table 2
Cytotoxic activity expressed by IC50 (mM) (95% CI) of compounds for cancer cell lines, obtained by nonlinear regression for all cell lines from three independent experiments.a
Compounds IC50 (mM) (CI 95%)
PBMC HL-60 MDA-MB435 HCT-8 SF295
3 >21.71 >21.71 >21.71 >21.71 >21.71
4 >10.91 >10.91 >10.91 >10.91 >10.91
5 >21.35 >21.35 >21.35 >21.35 >21.35
6 >10.72 >10.72 >10.72 >10.72 >10.72
7 >20.46 >20.46 >20.46 >20.46 >20.46
8 >10.27 >10.27 >10.27 >10.27 >10.27
9 >20.13 >20.13 >20.13 >20.13 >20.13
10 >10.10 >10.10 >10.10 >10.10 >10.10
12 >11.72 >11.72 >11.72 >11.72 >11.72
13 >23.12 >23.12 >23.12 >23.12 >23.12
14 >11.61 >11.61 >11.61 >11.61 >11.61
15 >22.70 >22.70 >22.70 3.99 (2.54e6.31) >22.70
16 >11.40 >11.40 >11.40 >11.40 >11.40
17 >14.43 >14.43 >14.43 >14.43 >14.43
18 >15.41 >15.41 >15.41 >15.41 >15.41
19 >14.60 >14.60 >14.60 >14.60 >14.60
20 >14.60 >14.60 >14.60 >14.60 >14.60
21 >14.60 >14.60 >14.60 >14.60 >14.60
22 >14.77 >14.77 >14.77 >14.77 >14.77
23 >14.77 >14.77 >14.77 >14.77 >14.77
24 >14.77 >14.77 >14.77 >14.77 >14.77
25 >14.69 >14.69 >14.69 3.64 (2.90e4.55) 3.87 (2.99e5.02)
26 >14.69 >14.69 >14.69 >14.69 >14.69
27 >14.69 >14.69 >14.69 >14.69 >14.69
28 >13.61 >13.61 >13.61 >13.61 >13.61
31 11.3 (9.74e13.17) 5.68 (5.13e7.97) 3.97 (3.23e4.91) 12.39 (11.20e13.72) >13.80
32 3.58 (3.34e3.86) 1.43 (1.32e1.54) 1.54 (1.46e1.62) 2.42 (2.31e2.54) 1.93 (1.76e2.12)
33 2.08 (1.80e2.41) 1.01 (0.92e1.11) 1.22 (0.88e1.74) 1.37 (1.27e1.50) 1.55 (1.20e1.55)
34 4.01 (3.53e4.49) 1.67 (1.56e1.82) 1.99 (1.74e2.31) 2.24 (2.11e2.41) 2.33 (2.02e2.72)
35 3.37 (3.00e3.81) 1.20 (1.03e1.38) 1.20 (1.03e1.40) 2.26 (2.13e2.40) 1.76 (1.47e2.11)
36 2.52 (2.16e2.95) 1.88 (1.69e2.08) 1.92 (1.61e2.28) 3.21(2.89e3.60) 3.01 (2.32e3.88)
Hooker’s ‘lapachol peroxide’b
O
O
O
O
O
O
>10.36 >10.36 >10.36 9.76 (7.10e13.40) >10.36
b-lapachonec >20.6 1.65 (1.49e1.78) 0.25 (0.16e0.33) 0.83 (0.74e0.87) 0.91 (0.74e1.11)
Nor-b-lapachonec >21.9 1.75 (nd) 0.31 (0.22e0.39) 1.36 (1.18e1.53) 1.58(1.31e1.88)
Doxorubicinc 0.42 (0.18e0.69) 0.03 (0.02e0.04) 0.88 (0.62e1.21) 0.06 (0.04e0.08) 0.41 (0.29e0.44)
a Alamar Blue assay was performed with human peripheral blood mononuclear cells (PBMC) after 72 h of drug exposure. Nd: not determined.
b Ref. [19].
c Refs. [15,16].
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(ENDOIII, also known as NTH). FPG is speciﬁc for oxidized purines,
specially for 8-oxo-7,8-dihydroguanine (8-oxoGua), and ENDOIII
recognizes oxidized pyrimidines, including thymine glycol and
uracil glycol [37].
Fig. 3 shows mean DNA damage caused by tested compounds,
expressed as DNA damage index after treatment with DNA-repair
enzymes ENDOIII and FPG. It was noted that the post-incubationTable 3
Effects of b-lapachone and nor-b-lapachone on DNA damage index for 24 h using alkalin
Compoundsa NACb DNA Damage index  S.E.M
HL-60
b-lapachone  61.36  4.15*
þ 8.33  0.25
Nor-b-lapachone  67.19  0.96*
þ 12.36  0.86
*p < 0.05 compared to cultures treated in the presence of NAC by ANOVA/Tukey’s test.
a Compounds were tested at 5 mM.
b N-acetylcysteine (NAC).results with the enzymes clearly show increased DNA migration of
the compounds-treated human cancer cells cultures. The results
indicate that the extent of oxidative DNA damage caused by
compounds, as recognized by ENDOIII and FPG in cancer cells, was
signiﬁcantly higher. The present quinonoid compounds-generated
ROS can attack DNA at both pyrimidine and purine bases, and lead
to strand breaks. Based on these results, we suggest that active
compounds facilitate DNA oxidative damage by ROS, such ase version of comet assay in the presence or absence of 5 mM NAC.
MDA-MB435 HCT-8 SF295
83.17  3.25* 72.41  2.56* 58.75  1.15*
5.16  0.10 11.41  1.15 8.72  2.25
78.52  1.11* 63.25  3.25* 63.81  0.75*
7.49  0.33 10.48  2.15 9.18  0.56
Fig. 3. Effects of FPG and ENDOIII on compounds (5 mM)-induced oxidative DNA damage after 12 h exposure by the alkaline version of the comet assay: HL-60 (A), MDA-MB435 (B),
HCT-8 (C), and SF295 (D). Bars represent the mean  S.E.M. of three independent experiments. *p < 0.05 vs. DMSO (0.1%) by ANOVA/Tukey’s test.
E.N. da Silva Jr. et al. / European Journal of Medicinal Chemistry 46 (2011) 399e410 403superoxide radical (O2) and hydrogen peroxide (H2O2). H2O2 is
not toxic by itself, but its high in vivo reactivity, through the Fenton
reaction, where it reacts with partially reduced metal ions, gener-
ates hydroxyl radical (HO), the most important radical in ROS-
related DNA damage [38]. These radicals cause a variety of base
lesions in DNA. In the case of tested compounds, the lesionFig. 4. Determination of TBARS of cancer cells [HL-60 (A), MDA-MB435 (B), HCT-8 (C), and S
(DMSO; 0.1%), H2O2 (10 mM for 2 h), or treatment with compounds. Filled bars represent th
exposure. Bars represent the mean  S.E.M. of three independent experiments. *p < 0.05 vproduced is probably 8-oxoGua, the preferred substrate for FPG
[39], and modiﬁed bases thymine glycol which is the more
commonly recognized lesion by ENDOIII [40]. NQs also react with
proteins and lipids, destroying their functionality, thereby causing
cell death [41]. Therefore, in order to get additional evidences of the
oxidative damage triggered by the present quinonoid compounds,F295 (D)] exposed to compounds (5 mM) for 24 h. Open bars represent negative control
e effect of pre-treatment with 5 mM N-acetylcysteine (NAC) added before compounds
s. DMSO (0.1%) by ANOVA/Tukey’s test.
Fig. 5. Effects of compounds 33 (A), 35 (B), b-lapachone (C), and nor- b-lapachone (D) at 5 mM on cancer cell viability using trypan blue dye exclusion after 24 h of incubation in the
presence or absence of 5 mM N-acetylcysteine (NAC) and 50 mM 1-bromoheptane (BH). Bars represent the mean  S.E.M. of three independent experiments. *p < 0.05 vs DMSO
(0.1%) by ANOVA/Tukey’s test.
E.N. da Silva Jr. et al. / European Journal of Medicinal Chemistry 46 (2011) 399e410404we examined the lipid peroxidation induced by these compounds.
As seen in Fig. 4, the treatment of cancer cells with active
substances resulted in an increase of TBARS formation. Pre-incu-
bation with NAC prevented the quinonoid compounds-generated
oxidative damage, as seen by the reduced level of TBARS.Fig. 6. Effect of compounds (33 and 35) at 5 mM on the induction of DNA strand breaks in h
the presence or absence of 5 mM N-acetylcysteine (NAC) and 50 mM 1-bromoheptane (BH): H
of three independent experiments. *p < 0.05 vs DMSO (0.1%) by ANOVA/Tukey’s test.These data corroborate other reports, which showed that
b-lapachone, related compounds and other NQs induce ROS
production and oxidative DNA damage [42].
Compounds 33 and 35 promoted cell death by apoptosis and
genotoxicity [DNA strand breaks were reduced after pre-treatmentuman cancer cell lines after 24 h exposure by the alkaline version of the comet assay in
L-60 (A), MDA-MB435 (B), HCT-8 (C), and SF295 (D). Bars represent the mean  S.E.M.
Fig. 7. Induction of cancer cells apoptosis by compounds (33 and 35) at 5 mM using acridine-orange and ethidium-bromide staining (AO/EB), and determined by ﬂuorescence
microscopy count after 24 h of incubation in the presence or absence of 5 mM N-acetylcysteine (NAC) and 50 mM 1-bromoheptane (BH): HL-60 (A), MDA-MB435 (B), HCT-8 (C), and
SF295 (D). Bars represent the mean  S.E.M. of three independent experiments. *p < 0.05 vs DMSO (0.1%) by ANOVA/Tukey’s test.
Table 4
Effects of anthraquinone imidazoles, ethers quinones and Hooker’s ‘lapachol
peroxide’ on cancer cell apoptosis at 5 mM using acridine-orange and ethidium-
bromide staining (AO/EB). Apoptotic nuclei were determined by ﬂuorescence
microscopy analysis after 24 h of exposure in the presence or absence 50 mM BH.
Compoundsa BHb Apoptotic nuclei (%)  S.E.M.
HL-60 MDA-MB435 HCT-8 SF295
H2O2c  83.17  4.15* 74.59  3.75* 80.66  5.16* 85.03  7.15*
18 þ 8.37  2.45 11.44  0.81 8.11  0.10 9.17  0.96
 12.59  4.10 9.02  0.75 10.35  0.10 7.32  0.11
22 þ 10.75  0.56 10.38  0.10 9.17  1.45 13.95  3.45
 11.47  1.75 6.33  0.33 5.33  0.33 11.85  0.81
23 þ 6.18  0.81 6.17  0.56 7.28  0.11 7.38  1.15
 7.33  1.17 9.81  0.11 12.01  0.10 10.05  0.10
24 þ 9.62  0.56 12.27  3.15 9.31  0.33 4.17  0.10
 5.27  0.11 7.49  0.25 8.72  1.17 5.82  0.10
25 þ 12.59  2.45 10.04  0.21 4.19  0.10 9.91  0.75
 8.21  0.75 7.39  0.33 6.48  0.56 11.73  1.17
26 þ 8.17  0.33 13.75  0.56 7.25  0.45 9.66  0.10
 10.49  1.15 12.51  0.10 12.73  2.45 13.51  3.15
27 þ 14.26  3.45 13.07  1.15 11.16  0.11 10.18  0.56
 10.70  2.08 9.56  1.75 8.51  0.75 5.93  0.11
8 þ 4.17  0.11 7.44  1.05 11.46  0.10 8.01  0.10
 8.13  0.17 9.51  1.25 8.71  1.05 7.94  0.56
10 þ 10.62  0.25 13.72  2.45 10.33  0.11 12.06  2.25
 10.21  1.15 8.38  0.75 5.85  0.25 8.33  0.75
12 þ 8.55  0.11 11.36  1.15 9.37  0.15 11.47  0.11
 3.91  0.11 7.94  0.10 12.52  0.75 8.30  0.10
16 þ 11.04  0.15 12.09  2.45 11.70  1.15 13.97  0.33
 9.13  3.15 8.56  0.10 9.27  0.11 11.73  1.15
Hooker’s
‘lapachol
peroxide’d
þ 8.46  0.15 5.82  0.11 9.16  0.33 7.30  0.21
 11.17  0.33 4.72  0.25 8.52  0.10 11.45  0.15
*p < 0.05 compared to cultures treated in the presence or absence of BH by ANOVA/
Tukey’s test.
a Compounds were tested at 5 mM.
b 1-Bromoheptane (BH).
c H2O2 at 10 mM during 2 h.
d Ref. [19].
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blue stain)], suggesting that tested quinones-induced apoptosis is
associatedwith ROS production (Figs. 5e7). Moreover, emphasizing
the ROS contribution on the cellular toxicity, the GSH content was
depleted by using a non-toxic concentration of 1-bromoheptane
(trypan blue stain). In GSH-depleted cell cultures, an increase in cell
death (% apoptotic nuclei) as well as in the levels of DNA strand
breaks (comet assay), was observed.
The effects of anthraquinone imidazoles 18 and 22e27, ethers
quinones 8,10,12,16 and Hooker’s ‘lapachol peroxide’ [19] (inactive
compounds) on cancer cell apoptosis at 5 mM using DNA-binding
ﬂuorescent dye (AO/EB) staining (Table 4) showed that these
substances do not generate ROS in this concentration, since the pre-
treatment with 1-bromoheptane did not show any inﬂuence on the
activity of these compounds. These data corroborate with the
inactivity in cancer cell lines.
4. Conclusions
In this paper, we listed a series of new NQs that were evaluated
against tumor cell lines. Only the b-lapachone-based 1,2,3-triazoles
were highly active (IC50 < 2 mM) for cancer cell lines, for instance,
HL-60 and MDA-MB435, inducing apoptotic cell death mediated by
ROS generation, similarly to the precursor molecules. Thus, the
b-lapachone-based 1,2,3-triazoles can be considered promising
prototypes for cancer therapy.
5. Experimental
5.1. Chemistry
Melting points were obtained on Thomas Hoover and are
uncorrected. Analytical grade solvents were used. Column chro-
matography was performed on silica gel (Acros Organics 0.035e
E.N. da Silva Jr. et al. / European Journal of Medicinal Chemistry 46 (2011) 399e4104060.070 mm, pore diameter ca 6 nm). Infrared spectra were recorded
on a PerkineElmer FT-IR Spectrometer. 1H and 13C NMR were
recorded at room temperature using a VarianMercury Plus 300 and
Varian MR 400 instrument, in the solvents indicated, with TMS as
internal standard. Chemical shifts (d) are given in ppm and coupling
constants (J) in Hertz. High-resolution mass spectra (electrospray
ionization) were obtained using a MicroTOF Ic - Bruker Daltonics.
All the compounds were nominated using the program CS Chem-
Draw Ultra version 5.0 and 10.0.
5.2. General procedures to prepare the ether-compounds
The hydroxyquinone in glacial acetic acid was heated to boiling,
the source of heat was removed, and lead dioxide was added. The
hotmixturewas shaken for 2min and ﬁltered to remove lead oxide,
and after precipitation on cooling, very slowly, and ﬁltration,
crystals of the ether were obtained [19].
5.2.1. 3-(3-Methyl-butyl)-3-[3-(3-methyl-butyl)-1,4-dioxo-1,4-
dihydro-naphthalen-2-yloxy]-naphthalene-1,2,4-trione 8
The reaction of 2-hydroxy-3-(3-methyl-butyl)-[1,4]naph-
thoquinone (7), (244 mg, 1 mmol), 2.5 mL of AcOH and 244 mg of
PbO2 yielded product 8, (388 mg, 0.8 mmol, 80% yield) as an orange
solid; mp 77e81 C; IR (KBr) 1747 (C]O),1697 (C]O), 1649 (C]O),
1593 (C]O), 1577 (C]O) cm1; 1H NMR (300 MHz, CDCl3)
d 8.44e8.41 (1H, m), 8.24e8.21 (1H, m), 8.04e8.00 (1H, m),
7.96e7.92 (2H, m), 7.67e7.62 (2H, m), 7.53e7.48 (1H, m), 2.82e2.77
(2H, m), 2.06e1.99 (2H, m), 1.78e1.25 (6H, m), 1.02 (6H, d,
J ¼ 6.4 Hz), 0.85e0.81 (6H, m); 13C NMR (75 MHz, CDCl3) d 189.0
(C]O),184.3 (C]O),184.2 (C]O),182.0 (C]O),180.7 (C]O),150.8,
136.1, 134.8, 134.4, 133.9, 133.6, 132.9, 131.6, 130.6, 129.0, 128.5,
126.5, 126.1, 93.1, 36.9, 35.5, 31.5, 28.8, 27.9, 22.5, 22.4, 22.2; EI/
HRMS (m/z) [M þ H]þ 487.2124. Calcd for [C30H30O6H]þ: 487.2121.
5.2.2. 3-(3-Methyl-butyl)-3-[3-(3-methyl-butyl)-1,4-dioxo-
1,4,5,6,7,8-hexahydro-naphthalen-2-yloxy]-5,6,7,8-tetrahydro-
naphthalene-1,2,4-trione 10
The reaction of 2-hydroxy-3-(3-methyl-butyl)-5,6,7,8-tetrahy-
dro-[1,4]naphthoquinone (9), (248 mg, 1 mmol), 2.5 mL of AcOH
and 248 mg of PbO2 yielded product 10, (370 mg, 0.7 mmol, 75%
yield) as an orange solid; mp 74e78 C; IR (KBr) 1749 (C]O), 1683
(C]O), 1639 (C]O), 1604 (C]O) cm1; 1H NMR (300 MHz, CDCl3)
d 2.85e2.53 (4H, m), 2.20e1.15 (22H, m), 0.95 (6H, d, J ¼ 6.4 Hz),
0.85 (6H, d, J ¼ 6.4 Hz); 13C NMR (75 MHz, CDCl3) d 190.5 (C]O),
187.1 (C]O), 184.4 (C]O), 184.1 (C]O), 182.1 (C]O), 149.3, 147.1,
143.2, 139.7, 129.5, 92.2, 37.2, 36.3, 32.0, 29.0, 28.2, 24.5, 23.4, 23.2,
23.0, 22.7, 22.5, 22.4, 22.3, 21.8, 21.2, 21.1, 21.0; EI/HRMS (m/z)
[M þ H]þ 495.2731. Calcd for [C30H38O6H]þ: 495.2747.
5.2.3. 3-Isobutyl-3-(3-isobutyl-1,4-dioxo-1,4-dihydro-naphthalen-
2-yloxy)-naphthalene-1,2,4-trione 4
The reaction of 2-hydroxy-3-isobutyl-[1,4]-naphthoquinone (3),
(230 mg, 1 mmol), 2.5 mL of AcOH and 230 mg of PbO2 yielded
product 4, (320 mg, 0.70 mmol, 70% yield) as an orange solid; mp
79e80 C; IR (KBr) 1749 (C]O), 1701 (C]O), 1651 (C]O), 1593 (C]
O), 1575 (C]O) cm1; 1H NMR (300 MHz, CDCl3) d 8.43e8.40 (1H,
m), 8.23e8.20 (1H, m), 8.05e8.01 (1H, m), 7.96e7.92 (2H, m),
7.68e7.62 (2H, m), 7.54e7.48 (1H, m), 2.74 (2H, d, J ¼ 7.4 Hz),
2.31e1.94 (2H, m), 1.94 (2H, d, J ¼ 7.4 Hz), 1.07 (3H, d, J ¼ 1.6 Hz),
1.07 (3H, d, J ¼ 1.6 Hz), 0.97 (3H, d, J ¼ 6.5 Hz), 0.91 (3H, d,
J ¼ 6.5 Hz); 13C NMR (75 MHz, CDCl3) d 188.8 (C]O), 184.5 (C]O),
184.3 (C]O), 182.1 (C]O), 181.0 (C]O), 151.3, 136.1, 134.7, 134.4,
134.1, 132.9, 132.8, 132.5, 131.5, 130.7, 129.0, 128.5, 126.5, 126.2, 94.0,
45.8, 32.8, 28.4, 24.0, 23.9, 23.1, 23.0; EI/HRMS (m/z) [M þ H]þ
459.1802. Calcd for [C28H26O6H]þ: 459.1808.5.2.4. 3-Isobutyl-3-(3-isobutyl-1,4-dioxo-1,4,5,6,7,8-hexahydro-
naphthalen-2-yloxy)-5,6,7,8-tetrahydro-naphthalene-1,2,4-trione 6
The reaction of 2-hydroxy-3-isobutyl-5,6,7,8-tetrahydro-[1,4]
naphthoquinone (5), (234mg,1 mmol), 2.5 mL of AcOH and 234mg
of PbO2 yielded product 6, (326 mg, 0.7 mmol, 70% yield) as an
orange solid; mp 78e82 C; IR (KBr) 1749 (C]O), 1683 (C]O), 1641
(C]O), 1602 (C]O) cm1; 1H NMR (300 MHz, CDCl3) d 2.84e2.61
(2H, m), 2.51e2.32 (5H, m), 2.20e2.04 (2H, m), 1.91e1.77 (6H, m),
1.66e1.51 (5H, m), 0.98 (3H, d, J ¼ 1.8 Hz), 0.96 (3H, d, J ¼ 1.8 Hz),
0.93 (3H, d, J ¼ 6.5 Hz), 0.90 (3H, d, J ¼ 6.5 Hz); 13C NMR (75 MHz,
CDCl3) d 190.0 (C]O),187.1 (C]O),184.0 (C]O),183.8 (C]O),182.1
(C]O), 149.2, 146.6, 142.7, 139.5, 128.1, 92.7, 46.6, 32.1, 28.2, 24.3,
23.9, 23.8, 23.0, 22.9, 22.0, 21.0, 20.8, 20.7; EI/HRMS (m/z) [M þ H]þ
467.2441. Calcd for [C28H34O6H]þ: 467.2434.
5.2.5. 3-Allyl-3-(3-allyl-1,4-dioxo-1,4-dihydro-naphthalen-2-
yloxy)-naphthalene-1,2,4-trione 12
The reaction of 2-allyl-3-hydroxy-[1,4]naphthoquinone (11),
(214 mg, 1 mmol), 2.5 mL of AcOH and 214 mg of PbO2 yielded
product 12, (319 mg, 0.7 mmol, 70% yield) as an orange solid; mp
93e95 C; IR (KBr) 1747 (C]O), 1699 (C]O), 1651 (C]O), 1591 (C]
O), 1577 (C]O) cm1; 1H NMR (300 MHz, CDCl3) d 8.45e8.39 (1H,
m), 8.28e8.17 (1H, m), 8.06e8.01 (1H, m), 7.97e7.91 (2H, m),
7.70e7.63 (2H, m), 7.59e7.49 (1H, m), 6.08e5.95 (1H, m), 5.78e5.64
(1H, m), 5.35e5.27 (1H, m), 5.19e5.13 (2H, m), 5.12e5.05 (1H, m),
3.58e3.55 (2H, m), 2.85e2.82 (2H, m); 13C NMR (75 MHz, CDCl3)
d 188.5 (C]O), 184.0 (C]O), 183.6 (C]O), 182.0 (C]O), 180.0 (C]
O), 150.0, 136.6, 134.9, 134.6, 133.8, 133.0, 131.3, 130.3, 130.0, 129.0,
128.3,128.2,126.4,126.1,126.1,116.8, 92.7, 42.0, 27.9; EI/HRMS (m/z)
[M þ H]þ 427.1175. Calcd for [C26H18O6H]þ: 427.1182.
5.2.6. 3-(1,4-Dioxo-3-propyl-1,4-dihydro-naphthalen-2-yloxy)-3-
propyl-naphthalene-1,2,4-trione 14
The reaction of 2-hydroxy-3-propyl-[1,4]naphthoquinone (13),
(216mg,1mmol), 2.5mLofAcOHand216mgof PbO2yieldedproduct
14, (301mg, 0.7mmol, 70%yield) as an orange solid;mp89e91 C; IR
(KBr) 1747 (C]O),1701 (C]O),1651 (C]O),1593 (C]O),1577 (C]O)
cm1; 1HNMR (300MHz, CDCl3) d 8.43e7.48 (8H,m), 2.81e1.39 (8H,
m), 1.08 (3H, t, J ¼ 7.0 Hz), 0.91 (3H, t, J ¼ 7.0 Hz); 13C NMR (75 MHz,
CDCl3) d: 192.3 (C]O),189.0 (C]O),184.4 (C]O),184.3 (C]O),182.1
(C]O),151.0,136.1,135.0,134.4,134.0,133.1, 133.0,133.0,131.6, 130.6,
129.0, 128.4, 126.5, 126.2, 93.2, 39.5, 26.1, 21.6, 16.6, 14.5, 14.0.
5.2.7. 3-(1,4-Dioxo-3-propyl-1,4,5,6,7,8-hexahydro-naphthalen-2-
yloxy)-3-propyl-5,6,7,8-tetrahydro-naphthalene-1,2,4-trione 16
The reaction of 2-hydroxy-3-propyl-5,6,7,8-tetrahydro-[1,4]
naphthoquinone (15), (220 mg, 1 mmol), 2.5 mL of AcOH and
220 mg of PbO2 yielded product 16, (328 mg, 0.7 mmol, 70% yield)
as an orange solid; mp 71e94 C; IR (KBr) 1749 (C]O), 1683 (C]O),
1639 (C]O), 1604 (C]O) cm1; 1H NMR (300 MHz, CDCl3)
d 2.87e2.27 (8H, m), 2.16e1.25 (16H, m), 0.99 (3H, t, J¼ 7.0 Hz), 0.92
(3H, t, J ¼ 7.0 Hz); 13C NMR (75 MHz, CDCl3) d 190.5 (C]O), 187.2
(C]O), 184.1 (C]O), 183.0 (C]O), 182.0 (C]O), 149.4, 147.2, 143.1,
139.7, 129.1, 92.3, 40.2, 34.2, 25.6, 24.5, 23.4, 23.0, 22.3, 21.9, 21.2,
21.1, 21.0, 17.1, 14.6, 14.2; EI/HRMS (m/z) [M þ H]þ 439.2126. Calcd
for [C26H30O6H]þ: 439.2121.
5.2.8. 2-Methyl-3-(2-methyl-1,3-dioxo-indan-2-yloxy)-[1,4]
naphthoquinone 17
The reaction of 188 mg of phithiocol, 18.8 mL of AcOH and
188 mg of PbO2 yielded the compound 17, (311 mg, 0.9 mmol, 90%
yield) as a yellow prisms; mp 152e153 C; IR (KBr) 1754 (C]O),
1720 (C]O), 1655 (C]O), 1612 (C]O) cm1; 1H NMR (300 MHz,
CDCl3) d 8.07e8.00 (3H, m), 7.96e7.89 (2H, m), 7.67e7.60 (2H, m),
7.55e7.48 (1H, m), 2.27 (3H, s), 1.74 (3H, s); 13C NMR (75 MHz,
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134.2, 133.0, 132.0, 130.5, 130.3, 126.2, 124.1, 84.1, 23.4, 9.8. EI/HRMS
(m/z) [M þ Na]þ 369.0717. Calcd for [C21H14O5Na]þ: 369.0739.
5.3. General procedures to prepare the reduced compounds
3-Hydroxy-naphthoquinone was dissolved in the appropriate
solvent and submitted to catalytic reduction over 10 mol% of the
Pd/C as a catalyst. The reaction was monitored by TLC and after the
complete consumption of the quinone reactant the reaction
mixture was ﬁltered and the product was puriﬁed by column
chromatography in silica gel, eluted with an increasing polarity
gradient mixture of hexane and ethyl acetate.
5.3.1. 2-Hydroxy-3-isobutyl-5,6,7,8-tetrahydro-[1,4]
naphthoquinone 5
Nor-lapachol (2), (228 mg, 1 mmol) in 15 mL of AcOH, 55 psi of
H2 and 10% of Pd/C during 6 h, yielded product 5, (234 mg, 1 mmol,
100% yield) as a yellow solid; mp 88e90 C; IR (KBr) 1647 (C]O),
1631 (C]O), 3369 (-OH) cm1; 1H NMR (300 MHz, CDCl3) d 6.93
(OH, sl), 2.49e2.39 (4H, m), 2.31 (1H, d, J ¼ 7.2 Hz), 1.92e1.79 (1H,
m), 1.71e1.67 (4H, m), 0.89 (6H, d, J ¼ 6.5 Hz); 13C NMR (75 MHz,
CDCl3) d 187.5 (C]O), 183.4 (C]O), 151.0, 145.0, 137.7, 120.0, 31.6,
27.9, 23.1, 22.6, 21.8, 21.1, 21.0; MS [70 eV,m/z (%)]: 115 (8), 192 (11),
65 (13), 91 (17), 234 (17), 79 (27), 41 (100).
5.3.2. 2-Hydroxy-3-propyl-5,6,7,8-tetrahydro-[1,4]
naphthoquinone 15
C-Allyl lawsone (11), (214 mg, 1 mmol) in 15 mL of AcOH, 55 psi
of H2 and 10% of Pd/C during 6 h, yielded product 15, (220 mg,
0.98mmol, 98% yield) as a yellow solid; mp 65e67 C; IR (KBr) 1647
(C]O), 1618 (C]O) cm1; 1H NMR (300 MHz, CDCl3) d 2.51e2.35
(6H, m), 1.74e1.65 (4H, m), 1.48 (2H, sextet, J ¼ 7.5 Hz), 0.93 (1H, t,
J ¼ 7.4 Hz); 13C NMR (75 MHz, CDCl3) d 187.7 (C]O), 183.8 (C]O),
151.0, 145.2, 137.9, 120.8, 25.0, 23.2, 22.1, 21.8, 21.4, 21.2, 14.3; MS
[70 eV, m/z (%)]: 85 (70), 220 (80), 83 (100).
5.4. General procedure for the synthesis of the antraquinones
A solution of 1,2-diamino-anthraquinone (17a) (238mg,1mmol)
in 5mL of AcOH, sodium acetate (106mg,1.3mmol) and the desired
aldehyde (see below)were stirred in reﬂux. TLCwas used tomonitor
the end of the reaction. After the addition of water, the formed
precipitate was ﬁltered, and the product was puriﬁed by column
chromatography using as eluent a mixture of dichloromethane/
ethyl acetate (5:1).
5.4.1. 2-(2-Fluorophenyl)-1H-anthra[1,2-d]imidazole-6,11-dione 19
From 2-ﬂuoro-benzaldehyde (136mg,1.1mmol),19was obtained
as a yellow solid (207 mg, 0.61 mmol, 61% yield, mp 290e291 C).
IR (KBr) 3450, 1668, 1583, 1489, 1465, 1436, 1328, 1290, 1271,
765, 715, 605 cm1 1H NMR (400 MHz, DMSO-d6) d 11.81e11.64 (m,
1H), 8.54 (t, J ¼ 7.79 Hz, 1H), 8.38e8.34 (m, 1H), 8.34e8.30 (m, 1H),
8.27 (d, J ¼ 8.40 Hz, 1H), 8.16 (d, J¼ 8.39 Hz, 1H), 7.85e7.79 (m, 2H),
7.61e7.51 (m, 1H), 7.42e7.29 (m, 2H). 13C NMR (75 MHz, DMSO-d6)
d 183.5, 182.8, 164.5, 156.8, 134.9, 134.8, 133.4, 131.7, 131.6, 131.5,
131.4, 131.3, 128.7, 127.2, 126.6, 124.8, 121.5, 118.3, 118.0.
5.4.2. 2-(3-Fluorophenyl)-1H-anthra[1,2-d]imidazole-6,11-dione20
From 3-ﬂuoro-benzaldehyde (136 mg, 1.1 mmol), 20 was
obtained as a yellow solid (177 mg, 0.52 mmol, 52% yield, mp
250e255 C).
IR (KBr) 3414, 1670, 1647, 1587, 1577, 1529, 1485, 1458, 1328,
1294, 1274, 1188, 713 cm1 1H NMR (400 MHz, DMSO-d6)
d 11.38e11.29 (m, 1H), 8.38e8.33 (m, 1H), 8.32e8.28 (m, 1H), 8.26(d, J ¼ 8.42 Hz, 1H), 8.14 (d, J ¼ 8.37 Hz, 1H), 7.96e7.89 (m, 2H),
7.86e7.79 (m, 2H), 7.57 (dd, J ¼ 13.61, 7.92 Hz, 1H), 7.31e7.27 (m,
1H). 13C NMR (75 MHz, DMSO-d6) d 183.5, 182.8, 164.5, 156.8, 134.9,
134.8, 133.4, 131.7, 131.6, 131.5, 131.4, 131.3, 128.7, 127.2, 126.7, 124.7,
121.5, 118.3, 115.3.
5.4.3. 2-(4-Fluorophenyl)-1H-anthra[1,2-d]imidazole-6,11-dione 21
From4-ﬂuoro-benzaldehyde (136mg,1.1mmol), 21was obtained
as a yellow solid (226 mg, 0.66 mmol, 66% yield, mp 280e283 C).
IR (KBr) 3429, 1670, 1589, 1489, 1330, 1301, 1290, 717 cm1 1H
NMR (400 MHz, DMSO-d6) d 11.38e11.24 (m, 1H), 8.39e8.33 (m,
1H), 8.32e8.28 (m, 1H), 8.26 (d, J ¼ 8.36 Hz, 1H), 8.22e8.16 (m, 2H),
8.13 (d, J ¼ 8.43 Hz, 1H), 7.86e7.80 (m, 2H), 7.32e7.28 (m, 2H). 13C
NMR (75 MHz, DMSO-d6) d 183.0, 182.2, 156.6, 164.5, 134.9, 134.8,
134.3, 134.2, 132.9, 130.6, 130.5, 127.9, 126.6, 126.3, 126.1, 125.4,
120.9, 115.8, 115.5.
5.4.4. 2-o-Tolyl-1H-anthra[1,2-d]imidazole-6,11-dione 22
From 2-methyl-benzaldehyde (132 mg, 1.1 mmol), 22 was
obtained as a yellow solid (271 mg, 0.80 mmol, 80% yield, mp
235e239 C).
IR (KBr) 3346, 1666, 1649, 1575, 1519, 1483, 1438, 1323, 1296,
1008, 840, 773, 727, 713, 648 cm1 1H NMR (300 MHz, DMSO-d6)
d 8.27e8.19 (m,1H), 8.17e8.10 (m, 2H), 8.04 (d, J¼ 8.38 Hz,1H), 7.77
(d, J ¼ 7.42 Hz, 1H), 7.72e7.66 (m, 2H), 7.38e7.23 (m, 3H), 2.63 (s,
3H). 13C NMR (75 MHz, DMSO-d6) d 183.5, 183.0, 159.0, 137.9, 134.9,
134.7, 133.6, 131.3, 131.1, 130.6, 129.9, 128.4, 127.2, 126.7, 126.1, 125.5,
121.1, 21.1.
5.4.5. 2-m-Tolyl-1H-anthra[1,2-d]imidazole-6,11-dione 23
From 3-methyl-benzaldehyde (132 mg, 1.1 mmol), 23 was
obtained as a yellow solid (251 mg, 0.74 mmol, 74% yield, mp
229e231 C).
IR (KBr) 3444, 1670, 1581, 1525, 1489, 1330, 1290, 713, 684,
354 cm1 1H NMR (400 MHz, DMSO-d6) d 8.34e8.29 (m, 1H),
8.28e8.23 (m,1H), 8.21 (d, J¼ 8.37 Hz, 1H), 8.09 (d, J¼ 8.39 Hz, 1H),
7.98 (s, 1H), 7.92 (d, J ¼ 7.65 Hz, 1H), 7.82e7.76 (m, 2H), 7.45 (t,
J ¼ 7.62 Hz, 1H), 7.37 (d, J ¼ 7.60 Hz, 1H), 2.49 (s, 3H). 13C NMR
(100 MHz, DMSO-d6) d 182.8, 183.5, 158.2, 138.5, 134.8, 134.7, 133.5,
132.1, 129.2, 129.1, 128.4, 127.2, 126.6, 125.7, 121.4, 21.4.
5.4.6. 2-(2-Hydroxyphenyl)-1H-anthra[1,2-d]imidazole-6,11-
dione 25
From 2-hydroxy-benzaldehyde (150 mg, 1.1 mmol), 25 was
obtained as a yellow solid (174 mg, 0.51 mmol, 51% yield, mp
>300 C).
IR (KBr) 3352, 1664, 1589, 1521, 1487, 1327, 1290, 752, 713 cm1
1H NMR (300 MHz, DMSO-d6) d 12.68 (s, 1H), 12.11 (s, 1H), 8.32 (d,
J ¼ 7.4Hz, 1H), 8.14e8.10 (m, 2H), 7.99 (s, 2H), 7.85e7.82 (m, 2H),
7.43e7.37 (ddd, J ¼ 7.4 and 1.7Hz, 1H), 7.07e6.97 (m, 2H). 13C NMR
(75 MHz, DMSO-d6) d 183.6, 182.3, 157.3, 156.3, 134.6, 134.3, 133.2,
133.1, 132.9, 128.8, 127.9, 126.9, 126.3, 123.8, 121.4, 119.8, 117.2, 113.4.
5.4.7. 2-(3-Hydroxyphenyl)-1H-anthra[1,2-d]imidazole-6,11-
dione 26
From 3-hydroxy-benzaldehyde (150 mg, 1.1 mmol), 26 was
obtained as a yellow solid (200 mg, 0.59 mmol, 59% yield, mp
>300 C).
IR (KBr) 3530, 3410, 3020, 1658, 1580, 1535, 1488, 1462, 1440,
1325, 1290, 1264, 1234, 1153, 890, 784, 714, 680, 595, 568 cm1 1H
NMR (300 MHz, DMSO-d6) d 12.92 (s, 1H), 9.71 (s, 1H), 8.20e8.16
(m, 2H), 8.09e8.02 (m, 2H), 7.91e7.80 (m, 4H), 7.38 (t, J ¼ 7.8 Hz,
1H), 6.99 (dd, J ¼ 7.96 and 1.92 Hz, 1H). 13C NMR (75 MHz, DMSO-
d6) d 183.0, 182.3, 157.8, 157.6, 149.2, 134.4, 134.2, 133.0, 132.9, 132.8,
130.1, 129.8, 127.9, 126.7, 126.2, 124.9, 120.9, 119.1, 118.6, 118.2, 114.9.
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dione 27
From 4-hydroxy-benzaldehyde (150 mg, 1.1 mmol), 27 was
obtained as a yellow solid (187 mg, 0.55 mmol, 55% yield, mp
>300 C).
IR (KBr) 3431, 3134,1668,1608,1585,1490,1475,1458,1440,1328,
1295, 1246, 1174, 715 cm1 1H NMR (300 MHz, DMSO-d6) d 12.78 (s,
1H), 10.06 (s, 1H), 8.27 (d, J ¼ 8.37 Hz, 1H), 8.22e8.17 (m, 3H),
8.06e7.98 (m, 2H), 7.91e7.88 (m, 2H), 6.93 (d, J¼ 8.78, 2H). 13C NMR
(75 MHz, DMSO-d6) d 183.2, 182.3, 160.3, 158.2, 149.7, 134.4, 134.2,
133.2,133.0, 103.1, 127.4, 126.8,126.2,124.2, 121.0, 119.8, 118.2, 115.6.
5.4.9. 2-(4-Hydroxy-3-methoxyphenyl)-1H-anthra[1,2-d]
imidazole-6,11-dione 28
From 4-hydroxy-3-methoxy-benzaldehyde (167 mg, 1.1 mmol),
28 was obtained as a yellow solid (258 mg, 0.77 mmol, 77% yield,
mp >300 C).
IR (KBr) 3431, 3331, 1662, 1589, 1490, 1438, 1327, 1290, 1270,
1188, 1165, 1026, 721 cm1 1H NMR (400 MHz, DMSO-d6)
d 11.25e11.25 (s, 1H), 8.37 (dd, J ¼ 6.94, 2.11 Hz, 1H), 8.31 (dd,
J ¼ 6.88, 2.14 Hz, 1H), 8.25 (d, J ¼ 8.38 Hz, 1H), 8.11 (d, J ¼ 8.39 Hz,
1H), 7.85e7.80 (m, 3H), 7.62 (dd, J ¼ 8.27, 1.98 Hz, 1H), 7.11 (d,
J ¼ 8.24 Hz, 1H), 6.04e6.03 (m, 1H), 4.09e4.07 (s, 3H). 13C NMR
(100 MHz, DMSO-d6) d 183.6, 182.6, 158.6, 150.1, 148.1, 134.8,
134.6, 133.5, 133.4, 127.8, 127.1, 126.5, 122.4, 121.4, 120.4, 116.0,
112.1, 56.3.
5.5. X-ray analysis
A yellow crystal (0.242  0.225  0.132 mm3) of compound 17
was selected for X-ray diffraction. Intensity data were collected at
room temperature (T ¼ 298K) using a diffractometer Kappa CCD of
Enraf Nonius with MoKamonochromatic radiation (l ¼ 0.71073 Å)
and using the Collect [43] software, as well as Scalepack [44] for
cell reﬁnement. For compound 17 a total of 15300 reﬂections to
a maximum 2q of 25.76 were measured. The crystal structure for
compound 17 was solved by direct methods and reﬁned aniso-
tropically with full matrix least square on F2 using SHELXL-97
program [45]. H atoms attached to C atoms were located on
stereochemical grounds placed (CeH ¼ 0.93e0.98 Å) and reﬁned
as riding with Uiso(H) ¼ 1.5 Ueq(C-methyl) or 1.2 Ueq(other) times
the value of the equivalent isotropic displacement parameter of
atoms to which they are bonded. Compound 17 crystallized with
two water molecules. The software used were: data collection:
COLLECT [43]; cell reﬁnement: HKL SCALEPACK [44]; data reduc-
tion: HKL DENZO and SCALEPACK [44]. The program(s) used to
solve structure: SHELXS-97 [46]. The program(s) used to reﬁne
structure: SHELXL-97 [46] molecular graphics: ORTEP-3 [47],
software used to prepare material for publication: WinGX [47].
The main crystallographic parameters were inserted in the sup-
porting information.
Crystallographic data for compound 17 have been deposited
with the Cambridge Crystallographic Data Center as Supplemen-
tary Publication No. CCDC 742743. Copies of the data can be
obtained, free of charge, on application to CCDC, 12 Union Road,
Cambridge CH21EZ, UK (fax:þ44 1223 336 033 or e-mail: deposit@
ccdc.cam.ac.uk).
6. Anticancer assay
6.1. Chemicals
Fetal bovine serum and phytohaemagglutinin were purchased
from Cutilab (Campinas, SP, Brazil), and RPMI 1640 medium,
trypsineEDTA, penicillin and streptomycin were purchased fromGIBCO (Invitrogen, Carlsbad, CA, USA). 5-bromo-20-deoxyuridine,
thiobarbituric acid, hydrolyzed 1,1,3,3-tetramethoxypropan, 1-bro-
moheptane, N-acetylcysteine and colchicine were obtained from
Sigma Chemical Co. (St, Louis, MO). Hydrogen peroxide was from
Vetec (Brazil). Doxorubicin (Doxolem) was from Zodiac Produtos
Farmacêuticos S/A, Brazil. Low melting point agarose and agarose
were obtained from Invitrogen (Carlsbad, CA, USA). All other chem-
icals and reagents used were of analytical grade.
6.2. Cytotoxicity against cancer cell lines
Compounds (0.01e5 mg/mL) were tested for cytotoxic activity
against four cancer cell lines: SF295 (central nervous system), HCT-
8 (colon), MDA-MB435 (breast), HL-60 (leukemia) from National
Cancer Institute (Bethesda, MD). All cell lines were maintained in
RPMI 1640 medium supplemented with 10% fetal bovine serum,
2 mM glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin at
37 C with 5% CO2. Each compound was dissolved with DMSO to
obtain a concentration of 1 mg/mL. They were incubated with the
cells for 72 h. The negative control received the same amount of
DMSO (0.1% in the highest concentration). Doxorubicin
(0.1e0.58 mg/mL) was used as a positive control. The cell viability
was determined by reduction of the yellow dye 3-(4,5-dimethyl-2-
thiazol)-2,5-diphenyl-2H-tetrazolium bromide (MTT) to a blue
formazan product as described by Mosmann [27].
6.3. Inhibition of PBMC proliferation e Alamar Blue assay
To investigate the selectivity of compounds toward a normal
proliferating cell, the Alamar Blue assay was performed with
peripheral blood mononuclear cells (PBMC) after 72 h of drug
exposure. After 24 h, compounds (0.048e25 mg/mL) dissolved in
DMSO (0.1%) were added to each well and incubated for 72 h.
Doxorubicin (0.01e1.06 mM) was used as positive control. Twenty-
four h before the end of the incubation, 10 mL of stock solution
(0.312 mg/mL) of the Alamar Blue (Resazurin, SigmaeAldrich Co)
was added to each well. The absorbance was measured using
a multiplate reader (DTX 880 Multimode Detector, Beckman
Coulter) and the drug effect was quantiﬁed as the percentage of
control absorbance at 570 nm and 595 nm. The absorbance of Ala-
mar Blue in culturemedium ismeasured at a higherwavelength and
a lowerwavelength. The absorbanceof themedium is alsomeasured
at thehigher and lowerwavelengths. The absorbance of themedium
alone is subtracted fromtheabsorbanceofmediumplusAlamarBlue
at thehigherwavelength. This value is calledAOHW.Theabsorbance
of the medium alone is subtracted from the absorbance of medium
plusAlamar Blue at the lowerwavelength. This value is calledAOLW.
A correction factor, R0, can be calculated from AOHW and AOLW,
where R0¼ AOLW/AOHW. The percent Alamar Blue reduced is then
expressed as follows: % reduced ¼ ALW  (AHW  R0)  100.
6.4. Cells treatments
Cancer cell lines were treated with compounds (5 mM) during
24 h. Moreover, in order to evaluate the contribution of ROS on the
cytotoxicity and genotoxicity of tested compounds, cells were pre-
treated for 24 h with 5 mM N-acetylcysteine (NAC) or 50 mM 1-
bromoheptane (BH), and after they were exposed to tested
compounds (5 mM) during 24 h.
6.5. Cell viability
Cell viability was determined by the trypan blue dye exclusion
test in human cancer cell lines. After treatment trypan blue-
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aliquots removed from cultures after 24 h [48].
6.6. Morphological characterization of apoptotic cancer cells
Apoptotic cells were determined at the end of each treatment by
use of the acridine-orange (AO)/ethidium-bromide (EB) assay:
25 mL of the cell suspension were mixed with 1 mL of the staining
solution (AO 100 mg/mL þ EB 100 mg/mL in PBS) and spread on
a slide, and 300 cells were counted per data point [49]. The
percentage of apoptotic cells was then calculated.
6.7. Alkaline comet assay (single cell gel electrophoresis)
The alkaline comet assay was performed as described by Singh
et al. (1988) [50] with minor modiﬁcations [51], and following the
recommendations of the International Workshop on Genotoxicity
Test Procedures [52]. At the end of the treatment, cells were
washedwith ice-cold PBS, detachedwith 100 mL trypsin (0.15%) and
resuspended in complete RPMI medium. Next, 20 mL of cell
suspension (w106 cells/mL) were mixed with 0.75% low melting
point agarose and immediately spread onto a glass microscope
slide precoated with a layer of 1% normal melting point agarose.
The agarose was allowed to set at 4 C for 5 min. The slides were
incubated in ice-cold lysis solution (2.5MNaCl,10mMTris,100mM
EDTA, 1% Triton X-100 and 10% DMSO, pH 10.0) at 4 C for
a minimum of 1 h to remove cellular proteins, leaving the DNA as
“nucleoids.” After the lysis procedure, the slides were placed on
a horizontal electrophoresis unit. The unit was ﬁlled with fresh
buffer (300 mM NaOH and 1 mM EDTA, pH > 13.0) to cover the
slides for 20 min at 4 C to allow DNA unwinding and expression of
alkali-labile sites. Electrophoresis was conducted for 20 min at 25 V
and 300 mA (0.86 V/cm). After electrophoresis, the slides were
neutralized (0.4 M Tris, pH 7.5), stained with ethidium-bromide
(20 mg/mL) and analyzed using a ﬂuorescence microscope. All the
above steps were conducted under yellow light or in the dark to
prevent additional DNA damage. Images of 100 randomly selected
cells (50 cells from each of two replicate slides) were analyzed for
each concentration of test substance. Cells were scored visually and
assigned to one of ﬁve classes, according to tail size (from
undamaged-0, to maximally damaged-4), and a damage index
value was calculated for each sample of cells. Damage index thus
ranged from 0 (completely undamaged: 100 cells  0) to 400 (with
maximum damage: 100 cells  4) [53].
6.8. Measurement of oxidized purines and pyrimidines
Alkaline comet assay was performed as described above. At the
end of the treatment (5 mM during 12 h), slides were removed from
the lysing solution, and washed three times in enzyme buffer
(40 mM HEPES, 100 mM KCl, 0.5 mM Na2EDTA, 0.2 mg/mL BSA, pH
8.0), drained, and incubated with 70 mL FPG (30 min 37 C) or
ENDOIII (45 min 37 C) from New England BioLabs (USA). Images of
100 randomly selected cells (50 cells from each of two replicate
slides) were visually analyzed per group. The amount of oxidized
purines (FPG-sensitive sites) and pyrimidines (ENDOIII-sensitive
sites) was then determined by subtracting the amount of strand
breaks (samples incubated with buffer alone) to the total amount of
breaks obtained after incubation with FPG and ENDOIII.
6.9. Measurement of lipid peroxidation
The extent of compounds-induced lipid peroxidation was
determined by the reaction of thiobarbituric acid (TBA) with
malondialdehyde (MDA), a product formed by lipid peroxidation.The assays were performed by according to Salgo and Pryor (1996)
[54], with minor modiﬁcations. Cancer cells were incubated with
compounds (5 mM) for 24h, and after lysiswith TriseHCl (15mM for
1 h). Two milliliters 0.4 mg/mL TCA, 0.25 M HCl were added to the
lysate, which was then incubated with 6.7 mg/mL thrichloroacetic
acid for 15 min at 100 C. The mixture was centrifuged at 750g for
10 min. As TBA reacts with other products of lipid peroxidation in
addition to MDA, results are expressed in terms of thiobarbituric
reactive species (TBARS), which are determined by absorbance at
532 nm. Hydrolyzed 1,1,3,3-tetramethoxypropan was used as the
standard. The results were normalized by protein content [55].
Conﬂict of interest
Authors declare no conﬂict of interest.
Acknowledgments
This research was supported by grants from the Conselho
Nacional de Desenvolvimento Cientíﬁco e Tecnológico (CNPq),
Fundação Carlos Chagas Filho de Amparo à Pesquisa do Rio de
Janeiro (FAPERJ), CAPES, UnB, UFAL, UFRJ and National Cancer
Institute. The authors are also indebted to the PRONEX-FAPERJ
(E-26/110.574/2010) and to PRONEX-CNPq-FAPEAL. Dr. Eufrânio N.
da Silva Júnior thanks the CNPq for post doctoral ﬁnancial support
(project no. 151558/2009-4).
References
[1] E.A. Hillard, F.C. de Abreu, D.C.M. Ferreira, G. Jaouen, M.O.F. Goulart,
C. Amatore, Chem. Commun. (2008) 2612.
[2] (a) E.L. Bonifazi, C. Ríos-Luci, L.G. León, G. Burton, J.M. Padrón, R.I. Misico,
Bioorg. Med. Chem. 18 (2010) 2621;
(b) S.B. Ferreira, F.C. da Silva, F.A.F.M. Bezerra, M.C.S. Lourenço, C.R. Kaiser,
A.C. Pinto, V.F. Ferreira, Arch. Pharm. 343 (2010) 81.
[3] (a) E.N. da Silva Júnior, R.F.S. Menna-Barreto, M.C.F.R. Pinto, R.S.F. Silva,
D.V. Teixeira, M.C.B.V. de Souza, C.A. de Simone, S.L. de Castro, V.F. Ferreira,
A.V. Pinto, Eur. J. Med. Chem. 43 (2008) 1774;
(b) N. Kongkathip, B. Kongkathip, P. Siripong, C. Sangma, S. Luangkamin,
M. Niyomdecha, S. Pattanapa, S. Piyaviriyagul, P. Kongsaeree, Bioorg. Med.
Chem. 11 (2003) 3179.
[4] Y. Su, J. Xie, Y. Wang, X. Hub, X. Lin, Eur. J. Med. Chem. 45 (2010) 2713.
[5] N. Kongkathip, N. Pradidphol, K. Hasitapan, R. Grigg, W.C. Kao, C. Hunte,
N. Fisher, A.J. Warman, G.A. Biagini, P. Kongsaeree, P. Chuawong,
B. Kongkathip, J. Med. Chem. 53 (2010) 1211.
[6] R.C. Montenegro, A.J. Araújo, M.T. Molina, J.D.B.M. Filho, D.D. Rocha, E. Lopéz-
Montero, M.O.F. Goulart, E.S. Bento, A.P.N.N. Alves, C. Pessoa, M.O. de Moraes,
L.V. Costa-Lotufo, Chem. Biol. Interact. 184 (2010) 439.
[7] E. Pérez-Sacau, R.G. Díaz-Peñate, A. Estévez-Braun, A.G. Ravelo, J.M. García-
Castellano, L. Pardo, M. Campillo, J. Med. Chem. 50 (2007) 696.
[8] A.I. Francisco, A. Casellato, A.P. Neves, J.W.M. Carneiro, M.D. Vargas,
L.C. Visentin, A. Magalhães, C.A. Câmara, C. Pessoa, L.V. Costa-Lotufo,
J.D.B.M. Filho, M.O. de Moraes, J. Braz. Chem. Soc. 21 (2010) 169.
[9] A.I. Francisco, M.D. Vargas, T.P. Fragoso, J.W.M. Carneiro, A. Casellato, F.C. da
Silva, V.F. Ferreira, J.P. Barbosa, C. Pessoa, L.V. Costa-Lotufo, J.D.B.M. Filho,
M.O. de Moraes, A.S. Mangrich, J. Braz. Chem. Soc. 21 (2010) 1293.
[10] L.M. Lima, E.J. Barreiro, Curr. Med. Chem. 12 (2005) 23.
[11] C. Viegas Jr., A.C. Danuello, V.S. Bolzani, E.J. Barreiro, C.A.M. Fraga, Curr. Med.
Chem. 14 (2007) 1829.
[12] (a) M.V. Gil, M.J. Arevalo, O. Lopez, Synthesis 11 (2007) 1589;
(b) H.C. Kolb, M.G. Finn, K.B. Sharpless, Angew. Chem. Int. Ed. 40 (2001) 2004.
[13] Y.A. Al-Soud, N.A. Al-Masoudi, A. El-Rahman, S. Ferwanah, Bioorg. Med. Chem.
11 (2003) 1701.
[14] E.N. da Silva Júnior, M.A.B.F. de Moura, A.V. Pinto, M.C.F.R. Pinto, M.C.B.V. de
Souza, A.J. Araújo, C. Pessoa, L.V. Costa-Lotufo, R.C. Montenegro, M.O. de
Moraes, V.F. Ferreira, M.O.F. Goulart, J. Braz. Chem. Soc. 20 (2009) 635.
[15] E.N. da Silva Júnior, M.C.B.V. de Souza, A.V. Pinto, M.C.F.R. Pinto,
M.O.F. Goulart, F.W.A. Barros, C. Pessoa, L.V. Costa-Lotufo, R.C. Montenegro,
M.O. de Moraes, V.F. Ferreira, Bioorg. Med. Chem. 15 (2007) 7035.
[16] E.N. da Silva Júnior, C.F. de Deus, B.C. Cavalcanti, C. Pessoa, L.V. Costa-Lotufo,
R.C. Montenegro, M.O. de Moraes, M.C.F.R. Pinto, C.A. de Simone, V.F. Ferreira,
M.O.F. Goulart, C.K.Z. Andrade, A.V. Pinto, J. Med. Chem. 53 (2010) 504.
[17] M.G. Ettlinger, J. Am. Chem. Soc. 72 (1950) 3472.
[18] A.Y. Yakubovskaya, T.Y. Kochergina, V.A. Denisenko, D.V. Berdyshev,
V.P. Glazunov, V.P. Anufriev, Russ. Chem. Bull. Int. Ed. 55 (2006) 301.
[19] E.N. da Silva Júnior, M.C.F.R. Pinto, K.C.G. de Moura, C.A. de Simone,
C.J. Nascimento, C.K.Z. Andrade, A.V. Pinto, Tetrahedron Lett. 50 (2009) 1575.
E.N. da Silva Jr. et al. / European Journal of Medicinal Chemistry 46 (2011) 399e410410[20] E.N. da Silva Júnior, T.T. Guimarães, R.F.S. Menna-Barreto, M.C.F.R. Pinto,
C.A. de Simone, C. Pessoa, B.C. Cavalcanti, J.R. Sabino, C.K.Z. Andrade,
M.O.F. Goulart, S.L. de Castro, A.V. Pinto, Bioorg. Med. Chem. 18 (2010) 3224.
[21] M.C.F.R. Pinto, A.V. Pinto, C.G.T. Oliveira, An. Acad. Brasil. Ciências 52 (1980) 481.
[22] L.F. Fieser, M. Fieser, J. Am. Chem. Soc. 70 (1948) 3215.
[23] X. Peng, Y. Wu, J. Fan, M. Tian, K. Han, J. Org. Chem. 25 (2005) 10524.
[24] F.S. Cruz, B. Gilbert, J.N. Lopes, R. Pinchin, A.V. Pinto, Rev. Latinoamer. Quim 8
(1977) 140.
[25] (a) C.W. Tornøe, C. Christiensen, M. Meldal, J. Org. Chem. 67 (2002) 3057;
(b) V.V. Rostovtsev, G.L. Green, V.V. Fokin, K.B. Sharpless, Angew. Chem. Int.
Ed. 41 (2002) 2596.
[26] T.T. Guimarães, E.N. da Silva Júnior, C.E.M. Carvalho, C.A. de Simone, A.V. Pinto,
Acta Crystallogr. E65 (2009) o1063.
[27] T. Mosmann, J. Immunol. Methods 65 (1983) 55.
[28] (a) H. Louise, W. Jordana, G. Renate, A.R. John, Drug Metab. Lett. 1 (2007) 245;
(b) S. Subramanian, M.M.C. Ferreira, M. Trsic, Struct. Chem. 9 (1998) 47.
[29] A. Koceva-Chyla, B. Wieclawska, Z. Józwiak, M. Bryszewska, Cell Biol. Int. 30
(2006) 645.
[30] E.K. Choi, K. Terai, I.M. Ji, Y.H. Kook, K.H. Park, E.T. Oh, R.J. Grifﬁn, B.U. Lim,
J.S. Kim, D.S. Lee, D.A. Boothman, M. Loren, C.W. Song, H.J. Park, Neoplasia 9
(2007) 634.
[31] H.E. Poulsen, Exp. Toxicol. Pathol. 57 (2005) 161.
[32] (a) D.W. Nicholson, Nature 407 (2000) 810;
(b) M. Bamford, G. Walkinshaw, R. Brown, Exp. Cell Res. 256 (2000) 1;
(c) J.L. Fernandez-Luna, Clin. Transl. Oncol. 9 (2007) 555.
[33] S. Khan, P.J. O’Brien, Biochem. Biophys. Res. Commun. 179 (1991) 436.
[34] (a) A.S. Park, K.S. Choi, J.H. Bang, K. Huh, S.U. Kim, J. Neurochem. 75 (2000)
946;
(b) N. van Zandwij, Chest 107 (1995) 1437.
[35] (a) K. Ollinger, A. Brunmark, J. Biol. Chem. 266 (1991) 21496e21503;
(b) R. Zangh, O. Hirsch, M. Mohsen, A. Samuni, Arch. Biochem. Biophys. 312
(1994) 385e391;
(c) P.H. Lin, W.C. Pan, Y.W. Kang, Y.L. Chen, C.H. Lin, M.C. Lee, Y.H. Chou,
J. Nakamura, Chem. Res. Toxicol. 18 (2005) 1262e1270.
[36] S. Bjelland, E. Seeberg, Mutat. Res. 531 (2003) 37e80.
[37] (a) G. Speit, P. Schutz, I. Bonzheim, K. Trenz, H. Hoffmann, Toxicol. Lett. 146
(2004) 151e158;
(b) A.R. Collins, S.J. Duthie, V.L. Dobson, Carcinogenesis 14 (1993) 1733e1735.
[38] M. Valko, D. Leibfritz, J. Moncol, M.T. Cronin, M. Mazur, J. Telser, Int. J. Bio-
chem. Cell Biol. 39 (2007) 44e84.[39] C.C. Smith, M.R. O’Donovan, E.A. Martin, Mutagenesis 21 (2006) 185e190.
[40] H. Ide, Prog. Nucleic Acid Res. Mol. Biol. 68 (2001) 207e221.
[41] G.D. Bufﬁton, K. Ollinger, A. Brunmark, E. Cadenas, Biochem. J. 257 (1989)
561e571.
[42] (a) A.B. Pardee, Y.Z. Li, C.J. Li, Curr. Cancer Drug Targets 2 (2002) 227e242;
(b) A. Esteves-Souza, K.A. Lucio, A.S. da Cunha, A.C. Pinto, E.L.S. Lima,
C.A. Camara, M.D. Vargas, C.R. Gattass, Oncol. Rep. 20 (2008) 225e231;
(c) D.C.M. Ferreira, M.O.F. Goulart, M.S.A. Moreira, A.V. Pinto, I. Tapsoba,
S. Arbault, C. Amatore, ChemBioChem. 10 (2009) 528e538;
(d) B.K. Aithal, M.R. Kumar, B.N. Rao, N. Udupa, B.S. Rao, Cell Biol. Int. 33
(2009) 1039e1049;
(e) R.J. McKallip, C. Lombard, J. Sun, Toxicol. Appl. Pharmacol. 247 (2010)
41e52;
(f) V. Klaus, T. Hartmann, J. Gambini, P. Graf, W. Stahl, A. Hartwig, L.O. Klotz,
Arch. Biochem. Biophys. 496 (2010) 93e100.
[43] Enraf-Nonius, COLLECT. Nonius BV, Delft, The Netherlands, 1997e2000.
[44] Z. Otwinowski, W. Minor, H.K.L. Denzo and Scalepack. in: C.W. Carter Jr.,
R.M. Sweet (Eds.), Methods in Enzymology, vol. 276. Academic Press, New
York, 1997, pp. 307e326.
[45] G.M. Sheldrick, SHELXL-97. Program for Crystal Structures Analysis. Univ. of
Göttingen, Göttingen, Germany, 1997.
[46] G.M. Sheldrick, SHELXS-97. Program for Crystal Structure Resolution. Univ. of
Göttingen, Göttingen, Germany, 1997.
[47] L.J. Farrugia, J. Appl. Crystallogr. 30 (1997) 565 ORTEP3 for Windows.
[48] B.C. Cavalcanti, H.V.N. Júnior, M.H.R. Seleghim, R.G.S. Berlinck, G.M.A. Cunha,
M.O. Moraes, C. Pessoa, Chem. Biol. Interact. 174 (2008) 155.
[49] B.C. Cavalcanti, D.P. Bezerra, H.I.F. Magalhães, M.O. Moraes, A.S. Lima,
E.R. Silveira, C.A.G. Câmara, V.S. Rao, C. Pessoa, L.V. Costa-Lotufo, J. Appl.
Toxicol. 29 (2009) 560.
[50] N.P. Singh, M.T. McCoy, R.R. Tice, E.L. Scheider, Exp. Cell Res. 175 (1988) 184.
[51] A. Hartmann, G. Speit, Toxicol. Lett. 90 (1997) 183.
[52] R.R. Tice, E. Agurell, D. Anderson, B. Burlinson, A. Hartmann, H. Kobayashi,
Y. Miyamae, E. Rojas, J.C. Ryu, Y.F. Sasaki, Environ. Mol. Mutagen. 35 (2000)
206.
[53] B.C. Cavalcanti, J.R.O. Ferreira, D.J. Moura, R.M. Rosa, G.V. Furtado, R.R. Burbano,
E.R. Silveira, M.A.S. Lima, C.A.G. Camara, J. Safﬁ, J.A.P. Henriques, V.S.N. Rao,
L.V. Costa-Lotufo, M.O. Moraes, C. Pessoa, Mutat. Res. 701 (2010) 153.
[54] M.G. Salgo, W.A. Pryor, Arch. Biochem. Biophys. 333 (1996) 482e488.
[55] O.H. Lowry, N.J. Rosebrough, A.L. Farr, R.J. Randall, J. Biol. Chem. 193 (1951)
265e275.
